Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction

Area of Science:

• Cardiology
• Interventional Cardiology
• Thrombosis Research

Background:

• The initial three hours post-symptom onset are critical for myocardial salvage in ST-elevation myocardial infarction (STEMI).
• Early reperfusion strategies like primary percutaneous coronary intervention (PPCI) or pre-hospital fibrinolysis/glycoprotein IIb/IIIa-inhibitors (GPI) can restore coronary patency.
• Oral antiplatelet therapy may not provide sufficient platelet inhibition early on, and benefits diminish after the initial golden period.

Purpose of the Study:

• To review optimal antithrombotic treatment strategies for STEMI patients undergoing primary angioplasty.
• To discuss tailoring antithrombotic therapy based on coronary thrombotic burden, vascular approach, and bleeding risk.
• To highlight remaining challenges in STEMI management, including high-risk patients and dual antiplatelet therapy duration.

Main Methods:

• Review of current evidence and guidelines for antithrombotic therapy in STEMI.
• Analysis of treatment approaches based on patient presentation time and risk factors.
• Discussion of specific antithrombotic agents (GPI, bivalirudin, P2Y12 inhibitors) and their indications.

Main Results:

• A GPI-based approach may benefit early presenters with high thrombus burden, while bivalirudin without GPI suits higher bleeding risk patients.
• Oral P2Y12 inhibitors (prasugrel, ticagrelor) effectively prevent stent thrombosis and recurrent ischemic events post-PPCI.
• No data supports GPI use in bailout situations.

Conclusions:

• Antithrombotic treatment during primary angioplasty requires individualized tailoring based on clinical factors.
• Effective strategies exist for STEMI reperfusion, but challenges remain in managing high-risk bleeding patients and optimizing dual antiplatelet therapy duration.
• Further research is needed to address open issues in STEMI management.